STARTSEITE
Current issue
Archives
Impressum
Datenschutz
 
 
  SPOT ON
 

Post-marketing trials without tangible benefit

 
  NEW ON THE MARKET
 

Anti-interleukin-5 antibody reslizumab (CINQAERO) for severe eosinophilic asthma

 
  THERAPY FROM A CRITICAL VIEWPOINT
 

Delirium in palliative care: neuroleptics worse than placebo

Tapentadol (PALEXIA, YANTIL): What's new?

 
  IN BRIEF
 

Migraine prevention in children: is placebo the best medicine?

Death following overdose of colchicine - the package size of the drop formulation is to be limited

France: zolpidem (STILNOX, generics) -narcotic prescription required

Glucosamine and chondroitin in osteoarthritis without benefit in yet another study

 
  CURRENT ADR NETWORK REPORT
 

Urticaria with apixaban (ELIQUIS)

 
  SIDE EFFECTS
 

Malformations with hydroxyethylrutoside (e.g. VENORUTON)?

Fatalities with selexipag (UPTRAVI) in pulmonary hypertension

Rivaroxaban (XARELTO): agranulocytosis and STEVENS-JOHNSON syndrome

 
  e a-t IN THE INTERNET
 

Elbasvir plus Grazoprevir (ZEPATIER) for hepatitis C

Amputations with SGLT2 inhibitors

Once more: anaphylactic reactions with chlorhexidine

 

© arznei-telegramm 2/2017